{"count": 8, "results": [{"_id": "35620309", "pmid": 35620309, "title": "Amlodipine inhibits proliferation, invasion, and colony formation of breast cancer cells.", "journal": "Biomed Rep", "authors": ["Alqudah MAY", "Al-Samman R", "Azaizeh M", "Alzoubi KH"], "date": "2022-06-01T00:00:00Z", "doi": "10.3892/br.2022.1533", "meta_date_publication": "2022 Jun", "meta_volume": "16", "meta_issue": "6", "meta_pages": "50", "score": 50264.57, "text_hl": "@<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@Amlodipine@@@ inhibits proliferation, invasion, and colony formation of @<m>DISEASE_Breast_Neoplasms</m> @DISEASE_MESH:D001943 @@@breast cancer@@@ cells.", "citations": {"NLM": "Alqudah MAY, Al-Samman R, Azaizeh M, Alzoubi KH. Amlodipine inhibits proliferation, invasion, and colony formation of breast cancer cells. Biomed Rep. 2022 Jun;16(6):50. PMID: 35620309", "BibTeX": "@article{35620309, title={Amlodipine inhibits proliferation, invasion, and colony formation of breast cancer cells.}, author={Alqudah MAY and Al-Samman R and Azaizeh M and Alzoubi KH}, journal={Biomed Rep}, volume={16}, number={6}, pages={50}}"}}, {"_id": "33240477", "pmid": 33240477, "pmcid": "PMC7675855", "title": "Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes", "journal": "Ther Adv Chronic Dis", "authors": ["Potmešil P", "Szotkowská R"], "date": "2020-11-16T00:00:00Z", "doi": "10.1177/2040622320964152", "meta_date_publication": "2020", "meta_volume": "11", "meta_issue": "", "meta_pages": "2040622320964152", "score": 50250.95, "text_hl": "The efflux function of @GENE_ABCC2 @GENE_1244 @@@multidrug resistance protein 2@@@ is known to be reduced by @CHEMICAL_Telmisartan @CHEMICAL_MESH:D000077333 @@@telmisartan@@@ and @CHEMICAL_Tamoxifen @CHEMICAL_MESH:D013629 @@@tamoxifen@@@ and @<m>DISEASE_Breast_Neoplasms</m> @DISEASE_MESH:D001943 @@@breast cancer@@@ resistance protein is known to be inhibited by @CHEMICAL_Telmisartan @CHEMICAL_MESH:D000077333 @@@telmisartan@@@ and @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@. ", "citations": {"NLM": "Potmešil P, Szotkowská R. Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes Ther Adv Chronic Dis. 2020;11():2040622320964152. PMID: 33240477", "BibTeX": "@article{33240477, title={Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes}, author={Potmešil P and Szotkowská R}, journal={Ther Adv Chronic Dis}, volume={11}, pages={2040622320964152}}"}}, {"_id": "40702728", "pmid": 40702728, "title": "Amlodipine as an Immunomodulatory Agent in Cancer Therapy: Enhancing Dendritic Cell Activation in Combination with Tumor-associated Antigen.", "journal": "Mol Ther", "authors": ["Wang Z", "Huang X", "Duan L", "Tian S", "Shi C", "Mou Y", "Dong H", "Gao Y", "Weng L"], "date": "2025-07-23T00:00:00Z", "doi": "10.1016/j.ymthe.2025.07.030", "meta_date_publication": "2025 Jul 23", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50248.05, "text_hl": "Furthermore, when @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ was administered in conjunction with @CHEMICAL_Indocyanine_Green @CHEMICAL_MESH:D007208 @@@indocyanine green@@@ (@CHEMICAL_Indocyanine_Green @CHEMICAL_MESH:D007208 @@@ICG@@@) or @CHEMICAL_Doxorubicin @CHEMICAL_MESH:D004317 @@@doxorubicin@@@ (@CHEMICAL_Doxorubicin @CHEMICAL_MESH:D004317 @@@DOX@@@) therapy in @SPECIES_10090 @@@murine@@@ models of @CELLLINE_CVCL:0125 @@@4T1@@@ @<m>DISEASE_Breast_Neoplasms</m> @DISEASE_MESH:D001943 @@@breast cancer@@@ and @CELLLINE_CVCL:7254 @@@CT26@@@ @DISEASE_Colorectal_Neoplasms @DISEASE_MESH:D015179 @@@colon cancer@@@, we observed a notable activation of CD8+ T cell. ", "citations": {"NLM": "Wang Z, Huang X, Duan L, Tian S, Shi C, Mou Y, Dong H, Gao Y, Weng L. Amlodipine as an Immunomodulatory Agent in Cancer Therapy: Enhancing Dendritic Cell Activation in Combination with Tumor-associated Antigen. Mol Ther. 2025 Jul 23;():. PMID: 40702728", "BibTeX": "@article{40702728, title={Amlodipine as an Immunomodulatory Agent in Cancer Therapy: Enhancing Dendritic Cell Activation in Combination with Tumor-associated Antigen.}, author={Wang Z and Huang X and Duan L and Tian S and Shi C and Mou Y and Dong H and Gao Y and Weng L}, journal={Mol Ther}}"}}, {"_id": "35020688", "pmid": 35020688, "title": "Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study.", "journal": "J Cardiovasc Pharmacol", "authors": ["Chan TH", "Tsoi MF", "Yung Cheung BM"], "date": "2022-04-01T00:00:00Z", "doi": "10.1097/FJC.0000000000001217", "meta_date_publication": "2022 Apr 1", "meta_volume": "79", "meta_issue": "4", "meta_pages": "577-582", "score": 50243.473, "text_hl": "Adjusted incidence rate ratios of @CHEMICAL_Valsartan @CHEMICAL_MESH:D000068756 @@@valsartan@@@ relative to @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ were significant for @<m>DISEASE_Breast_Neoplasms</m> @DISEASE_MESH:D001943 @@@breast cancer@@@ (0.63, 0.46-0.86) only. ", "citations": {"NLM": "Chan TH, Tsoi MF, Yung Cheung BM. Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study. J Cardiovasc Pharmacol. 2022 Apr 1;79(4):577-582. PMID: 35020688", "BibTeX": "@article{35020688, title={Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study.}, author={Chan TH and Tsoi MF and Yung Cheung BM}, journal={J Cardiovasc Pharmacol}, volume={79}, number={4}, pages={577-582}}"}}, {"_id": "27822402", "pmid": 27822402, "pmcid": "PMC5086392", "title": "Formulations of Amlodipine: A Review", "journal": "J Pharm (Cairo)", "authors": ["Sheraz MA", "Ahsan SF", "Khan MF", "Ahmed S", "Ahmad I"], "date": "2016-01-01T00:00:00Z", "doi": "10.1155/2016/8961621", "meta_date_publication": "2016", "meta_volume": "2016", "meta_issue": "", "meta_pages": "8961621", "score": 50069.336, "text_hl": "Formulations of @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@Amlodipine@@@: A Review", "citations": {"NLM": "Sheraz MA, Ahsan SF, Khan MF, Ahmed S, Ahmad I. Formulations of Amlodipine: A Review J Pharm (Cairo). 2016;2016():8961621. PMID: 27822402", "BibTeX": "@article{27822402, title={Formulations of Amlodipine: A Review}, author={Sheraz MA and Ahsan SF and Khan MF and Ahmed S and Ahmad I}, journal={J Pharm (Cairo)}, volume={2016}, pages={8961621}}"}}, {"_id": "21062083", "pmid": 21062083, "title": "Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer.", "journal": "Mol Pharm", "authors": ["Zhang Y", "Li RJ", "Ying X", "Tian W", "Yao HJ", "Men Y", "Yu Y", "Zhang L", "Ju RJ", "Wang XX", "Zhou J", "Chen JX", "Li N", "Lu WL"], "date": "2011-02-07T00:00:00Z", "doi": "10.1021/mp100249x", "meta_date_publication": "2011 Feb 7", "meta_volume": "8", "meta_issue": "1", "meta_pages": "162-75", "score": 50055.477, "text_hl": "Targeting therapy with mitosomal @CHEMICAL_Daunorubicin @CHEMICAL_MESH:D003630 @@@daunorubicin@@@ plus @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ has the potential to circumvent intrinsic resistant @<m>DISEASE_Breast_Neoplasms</m> @DISEASE_MESH:D001943 @@@breast cancer@@@.", "citations": {"NLM": "Zhang Y, Li RJ, Ying X, Tian W, Yao HJ, Men Y, Yu Y, Zhang L, Ju RJ, Wang XX, Zhou J, Chen JX, Li N, Lu WL. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer. Mol Pharm. 2011 Feb 7;8(1):162-75. PMID: 21062083", "BibTeX": "@article{21062083, title={Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer.}, author={Zhang Y and Li RJ and Ying X and Tian W and Yao HJ and Men Y and Yu Y and Zhang L and Ju RJ and Wang XX and Zhou J and Chen JX and Li N and Lu WL}, journal={Mol Pharm}, volume={8}, number={1}, pages={162-75}}"}}, {"_id": "21646611", "pmid": 21646611, "title": "Radiation recall 5 years after whole-breast irradiation for early-stage breast cancer secondary to initiation of rosuvastatin and amlodipine.", "journal": "J Clin Oncol", "authors": ["Taunk NK", "Haffty BG", "Goyal S"], "date": "2011-08-01T00:00:00Z", "doi": "10.1200/JCO.2011.35.7202", "meta_date_publication": "2011 Aug 1", "meta_volume": "29", "meta_issue": "22", "meta_pages": "e661-3", "score": 50051.63, "text_hl": "Radiation recall 5 years after whole-breast irradiation for early-stage @<m>DISEASE_Breast_Neoplasms</m> @DISEASE_MESH:D001943 @@@breast cancer@@@ secondary to initiation of @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@rosuvastatin@@@ and @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@.", "citations": {"NLM": "Taunk NK, Haffty BG, Goyal S. Radiation recall 5 years after whole-breast irradiation for early-stage breast cancer secondary to initiation of rosuvastatin and amlodipine. J Clin Oncol. 2011 Aug 1;29(22):e661-3. PMID: 21646611", "BibTeX": "@article{21646611, title={Radiation recall 5 years after whole-breast irradiation for early-stage breast cancer secondary to initiation of rosuvastatin and amlodipine.}, author={Taunk NK and Haffty BG and Goyal S}, journal={J Clin Oncol}, volume={29}, number={22}, pages={e661-3}}"}}, {"_id": "1533173", "pmid": 1533173, "title": "Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse.", "journal": "Cancer Res", "authors": ["Taylor JM", "Simpson RU"], "date": "1992-05-01T00:00:00Z", "meta_date_publication": "1992 May 1", "meta_volume": "52", "meta_issue": "9", "meta_pages": "2413-8", "score": 50049.824, "text_hl": "These findings are important since they demonstrate that @<m>CHEMICAL_Amlodipine</m> @CHEMICAL_MESH:D017311 @@@amlodipine@@@ and other CCAs with known pharmacodynamics and side effects act to blunt @<m>DISEASE_Breast_Neoplasms</m> @DISEASE_MESH:D001943 @@@breast tumor@@@ progression in vivo.", "citations": {"NLM": "Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res. 1992 May 1;52(9):2413-8. PMID: 1533173", "BibTeX": "@article{1533173, title={Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse.}, author={Taylor JM and Simpson RU}, journal={Cancer Res}, volume={52}, number={9}, pages={2413-8}}"}}]}